Nasdaq:US$14.78 (+0.39) | HKEX:HK$22.94 (+0.06) | AIM:£2.19 (+0.02)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: An Open-Label Phase 1b/2 Study of Surufatinib in Combination with Tislelizumab  in Patients with Advanced Solid Tumors